- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: LLY-507 is a potent inhibitor of SMYD2 protein lysine methyltransferase activity, developed in a collaboration between the Structural Genomics Consortium (SGC) and Eli Lilly and Company .
Click here to link to the SGC's full list of epigenetics probes.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|LLY-507 is > 100-fold more selective for SMYD2 compared to other methyltransferases and other non-epigenetic targets .|
|Selectivity at enzymes|
|Key to terms and symbols||Click column headers to sort|